李树成,郭炳辰,高殿钰,王博,涂应锋

• 1:哈尔滨医科大学附属第一医院心血管内科

摘要(Abstract)：

心力衰竭是心血管疾病最主要的死亡原因，也是大多数心血管疾病的终末共同表现，全球约超过六千万人深受其影响。心脏移植目前仍是心力衰竭患者的治疗“金标准”，心力衰竭患者在遵循基础药物治疗的情况下可以改善生活质量，延长生存时间。但由于心力衰竭的复杂机制以及众多并发症，常规的心力衰竭治疗策略在临床工作中的局限性被逐渐放大。近年来，介入治疗作为一种新兴的心力衰竭的治疗手段，受到人们的关注并取得重大突破，为心力衰竭患者带来新的希望。其中，可注射水凝胶由于其微创性和有效输送治疗药物的能力，在生物医学领域的应用受到了极大的关注。在慢性心力衰竭领域，可注射水凝胶主要应用于组织再生、药物输送和免疫治疗等。本文主要阐述可注射水凝胶在心力衰竭治疗领域的应用及研究进展。

关键词(KeyWords)： 心力衰竭;介入治疗;可注射水凝胶

Abstract:

Keywords:

基金项目(Foundation): 哈尔滨医科大学附属第一医院科研创新基金项目（2024M32）

作者(Author): 李树成,郭炳辰,高殿钰,王博,涂应锋

参考文献(References)：

• [1]杨士伟，张薇，周玉杰.房间隔分流装置在心力衰竭介入治疗中的应用现状与前景[J].中国介入心脏病学杂志，2022,30(9):690-692. DOI:10. 3969/j. issn. 1004-8812. 2022. 09.009.
• [2]中国心血管健康与疾病报告编写组.《中国心血管健康与疾病报告2022》概要[J].中国介入心脏病学杂志，2023,31(7):485-508. DOI:10. 3969/j. issn. 1004-8812. 2023. 07. 002.
• [3] Vetter VC,Bouten CVC,van der Pol A. Hydrogels for cardiac restorative support:relevance of gelation mechanisms for prospective clinical use[J]. Curr Heart Fail Rep,2023,20(6):519-529. DOI:10.1007/s11897-023-00630-0.
• [4] Jen?a D,MelenovskyV,Stehlik J,et al. Heart failure after myocardial infarction:incidence and predictors[J]. ESC heart failure,2021,8(1):222-237. DOI:10.1002/ehf2.13144.
• [5] Frangogiannis NG. Pathophysiology of myocardial infarction[J]. Compr Physiol,2015,5(4):1841-1875. DOI:10.1002/cphy.c150006.
• [6] Koetting MC,Peters JT,Steichen SD,et al. Stimulusresponsive hydrogels:theory,modern advances,and applications[J]. Mater Sci Eng R Rep,2015,93:1-49.DOI:10.1016/j.mser.2015.04.001.
• [7] Slaughter BV,Khurshid SS,Fisher OZ,et al. Hydrogels in regenerative medicine[J]. Adv Mater,2009,21(32-33):3307-3329. DOI:10.1002/adma.200802106.
• [8] O’Neill HS,Gallagher LB,O’Sullivan J,et al. Biomaterialenhanced cell and drug delivery:lessons learned in the cardiac field and future perspectives[J]. Adv Mater,2016,28(27):5648-5661. DOI:10.1002/adma.201505349.
• [9] Ruvinov E,Cohen S. Alginate biomaterial for the treatment of myocardial infarction:progress,translational strategies,and clinical outlook:from ocean algae to patient bedside[J].Adv Drug Deliv Rev,2016,96:54-76. DOI:10.1016/j.addr.2015.04.021.
• [10] Wang L,Liu Y,Ye G,et al. Injectable and conductive cardiac patches repair infarcted myocardium in rats and minipigs[J].Nat Biomed Eng,2021,5(10):1157-1173. DOI:10.1038/s41551-021-00796-9.
• [11] Zhu J,Marchant RE. Design properties of hydrogel tissueengineering scaffolds[J]. Expert Rev Med Devices,2011,8(5):607-626. DOI:10.1586/erd.11.27.
• [12] Goonoo N. Tunable biomaterials for myocardial tissue regeneration:promising new strategies for advanced biointerface control and improved therapeutic outcomes[J]. Biomater Sci,2022,10(7):1626-1646. DOI:10.1039/d1bm01641e.
• [13] Li DS,Avazmohammadi R,Rodell CB,et al. How hydrogel inclusions modulate the local mechanical response in early and fully formed post-infarcted myocardium[J]. Acta Biomater,2020,114:296-306. DOI:10.1016/j.actbio.2020.07.046.
• [14] Chen MH,Wang LL,Chung JJ,et al. Methods to assess shearthinning hydrogels for application as injectable biomaterials[J].ACS Biomater Sci Eng,2017,3(12):3146-3160. DOI:10.1021/acsbiomaterials.7b00734.
• [15] Le HT,Mahara A,Fukazawa K,et al. Widely distributable and retainable in-situ gelling material for treating myocardial infarction[J]. Acta Biomater,2024,176:221-233. DOI:10.1016/j.actbio.2024.01.013.
• [16] Wen Y,Li XY,Li ZY,et al. Intra-myocardial delivery of a novel thermosensitive hydrogel inhibits post-infarct heart failure after degradation in rat[J]. J Cardiovasc Transl Res,2020,13(5):677-685. DOI:10.1007/s12265-019-09941-x.
• [17] He S,Zhang Z,Luo R,et al. Advances in injectable hydrogel strategies for heart failure treatment[J]. Adv Healthc Mater,2023,12(19):e2300029. DOI:10.1002/adhm.202300029.
• [18] Traverse JH,Henry TD,Dib N,et al. First-in-man study of a cardiac extracellular matrix hydrogel in early and late myocardial infarction patients[J]. JACC Basic Transl Sci,2019,4(6):659-669. DOI:10.1016/j.jacbts.2019.07.012.
• [19] Sazzad F,Kuzemczak M,Chen ZJ,et al. Transcatheter targeted myocardial restoration using hydrogel-based cell-free compound:toward an adoptable clinical protocol[J]. JTCVS Open,2023,13:184-196. DOI:10.1016/j.xjon.2022.12.008.
• [20] Wang B,Lee RJ,Tao L. First-in-human transcatheter endocardial alginate-hydrogel implantation for the treatment of heart failure[J]. Eur Heart J,2023,44(4):326. DOI:10.1093/eurheartj/ehac671.
• [21] Ma H,Gong W,Lim DS,et al. Echocardiography-guided percutaneous intramyocardial alginate hydrogel implants for heart failure:canine models with 6-month outcomes[J].Front Cardiovasc Med,2024,11:1320315. DOI:10.3389/fcvm.2024.1320315.
• [22] Kim H,Kim M,Im SK,et al. Mouse Cre-LoxP system:general principles to determine tissue-specific roles of target genes[J]. Lab Anim Res,2018,34(4):147-159. DOI:10.5625/lar.2018.34.4.147.
• [23] Chien WM,Liu Y,Dinca AA,et al. Injection-based delivery of cell-permeable peptide-tagged cre[J]. Methods Mol Biol,2017,1642:99-107. DOI:10.1007/978-1-4939-7169-5_7.
• [24] Shakya P,Brown ME,Davis ME. Encapsulation of pediatric cardiac-derived C-Kit(+)cells in cardiac extracellular matrix hydrogel for echocardiography-directed intramyocardial injection in rodents[J]. Methods Mol Biol,2022,2485:269-278.DOI:10.1007/978-1-0716-2261-2_18.
• [25] Hoeeg C,Dolatshahi-Pirouz A,Follin B. Injectable hydrogels for improving cardiac cell therapy-in vivo evidence and translational challenges[J]. Gels,2021,7(1):7. DOI:10.3390/gels7010007.
• [26] Malliaras K,Li TS,Luthringer D,et al. Safety and e fficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells[J]. Circulation,2012,125(1):100-112. DOI:10.1161/CIRCULATIONAHA.111.042598.
• [27] Alonaizan R,Carr C. Cardiac regeneration following myocardial infarction:the need for regeneration and a review of cardiac stromal cell populations used for transplantation[J]. Biochem Soc Trans, 2022, 50(1):269-281. DOI:10.1042/bst20210231.
• [28] Zhu D,Hou J,Qian M,et al. Nitrate-functionalized patch confers cardioprotection and improves heart repair after myocardial infarction via local nitric oxide delivery[J]. Nat Commun,2021,12(1):4501. DOI:10.1038/s41467-021-24804-3.
• [29] Wang H,Guo Y,Hu Y,et al. Ultrasound-controlled nano oxygen carriers enhancing cell viability in 3D GelMA hydrogel for the treatment of myocardial infarction[J]. Int J Biol Macromol,2023,244:125139. DOI:10.1016/j.ijbiomac.2023.125139.
• [30] Wang W,Tan B,Chen J,et al. An injectable conductive hydrogel encapsulating plasmid DNA-eNOs and ADSCs for treating myocardial infarction[J]. Biomaterials,2018,160:69-81. DOI:10.1016/j.biomaterials.2018.01.021.
• [31] Fisher SA,Zhang H,Doree C,et al. Stem cell treatment for acute myocardial infarction[J]. Cochrane Database Syst Rev,2015,2015(9):CD006536. DOI:10.1002/14651858.CD006536.pub4.
• [32] Gy?ngy?si M,Haller PM,Blake DJ,et al. Meta-analysis of cell therapy studies in heart failure and acute myocardial infarction[J]. Circ Res,2018,123(2):301-308. DOI:10.1161/CIRCRESAHA.117.311302.
• [33] Pasotti M,Prati F,Arbustini E. The pathology of myocardial infarction in the pre-and post-interventional era[J]. Heart,2006,92(11):1552-1556. DOI:10.1136/hrt.2005.086934.
• [34] Malliaras K,Marbán E. Cardiac cell therapy:where we’ve been,where we are,and where we should be headed[J].Br Med Bull,2011,98(1):161-185. DOI:10.1093/bmb/ldr018.
• [35] Leor J,Tuvia S,Guetta V,et al. Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine[J]. J Am Coll Cardiol,2009,54(11):1014-1023. DOI:10.1016/j.jacc.2009.06.010.
• [36] Golpanian S,Wolf A,Hatzistergos KE,et al. Rebuilding the damaged heart:mesenchymal stem cells,cell-based therapy,and engineered heart tissue[J]. Physiol Rev,2016,96(3):1127-1168. DOI:10.1152/physrev.00019.2015.
• [37] Fu H,Chen Q. Mesenchymal stem cell therapy for heart failure:a meta-analysis[J]. Herz,2020,45(6):557-563. DOI:10.1007/s00059-018-4762-7.
• [38] Xu Q,Xiao Z,Yang Q,et al. Hydrogel-based cardiac repair and regeneration function in the treatment of myocardial infarction[J]. Mater Today Bio,2024,25:100978. DOI:10.1016/j.mtbio.2024.100978.
• [39] Rao SV,Zeymer U,Douglas PS,et al. Bioabsorbable intracoronary matrix for prevention of ventricular remodeling after myocardial infarction[J]. J Am Coll Cardiol,2016,68(7):715-723. DOI:10.1016/j.jacc.2016.05.053.
• [40] Witman N,Heigwer J,Thaler B,et al. miR-128 regulates nonmyocyte hyperplasia,deposition of extracellular matrix and Islet1expression during newt cardiac regeneration[J]. Dev Biol,2013,383(2):253-263. DOI:10.1016/j.ydbio.2013.09.011.
• [41] Porrello ER,Johnson BA,Aurora AB,et al. MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes[J]. Circ Res,2011,109(6):670-679. DOI:10.1161/circresaha.111.248880.
• [42] Cakmak HA,Coskunpinar E,Ikitimur B,et al. The prognostic value of circulating microRNAs in heart failure:preliminary results from a genome-wide expression study[J]. JJ Cardiovasc Med(Hagerstown),2015,16(6):431-437. DOI:10.2459/jcm.0000000000000233.
• [43] Yang H,Qin X,Wang H,et al. An in vivo miRNA delivery system for restoring infarcted myocardium[J]. ACS Nano,2019,13(9):9880-9894. DOI:10.1021/acsnano.9b03343.
• [44] Kikuchi K,Poss KD. Cardiac regenerative capacity and mechanisms[J]. Annu Rev Cell Dev Biol,2012,28:719-741. DOI:10.1146/annurev-cellbio-101011-155739.
• [45] Nguyen TP,Qu Z,Weiss JN.Cardiacfibrosis and arrhythmogenesis:the road to repair is paved with perils[J]. J Mol Cell Cardiol,2014,70:83-91. DOI:10.1016/j.yjmcc.2013.10.018.
• [46] Masarone D,Limongelli G,Rubino M,et al. Management of arrhythmias in heart failure[J]. J Cardiovasc Dev Dis,2017,4(1):3. DOI:10.3390/jcdd4010003.
• [47] He S,Wu J,Li SH,et al. The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure[J]. Biomaterials,2020,258:120285. DOI:10.1016/j.biomaterials.2020.120285.
• [48] Shin M,Song KH,Burrell JC,et al. Injectable and conductive granular hydrogels for 3D printing and electroactive tissue support[J]. Adv Sci(Weinh),2019,6(20):1901229. DOI:10.1002/advs.201901229.
• [49] Liang S,Zhang Y,Wang H,et al. Paintable and rapidly bondable conductive hydrogels as therapeutic cardiac patches[J]. Adv Mater,2018,30(23):e1704235. DOI:10.1002/adma.201704235.
• [50] Zhu S,Yu C,Liu N,et al. Injectable conductive gelatin methacrylate/oxidized dextran hydrogel encapsulating umbilical cord mesenchymal stem cells for myocardial infarction treatment[J]. Bioact Mater,2022,13:119-134. DOI:10.1016/j.bioactmat.2021.11.011.
• [51] Kanelidis AJ,Premer C,Lopez J,et al. Route of delivery modulates the efficacy of mesenchymal stem cell therapy for myocardial infarction:a meta-analysis of preclinical studies and clinical trials[J]. Circ Res,2017,120(7):1139-1150.DOI:10.1161/circresaha.116.309819.
• [52] Zhang J,Zhu W,Radisic M,et al. Can we engineer a human cardiac patch for therapy?[J] Circ Res,2018,123(2):244-265. DOI:10.1161/CIRCRESAHA.118.311213.
• [53] Zhang D,Shadrin IY,Lam J,et al. Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes[J]. Biomaterials,2013,34(23):5813-5820. DOI:10.1016/j.biomaterials.2013.04.026.
• [54] Zhu D,Li Z,Huang K,et al. Minimally invasive delivery of therapeutic agents by hydrogel injection into the pericardial cavity for cardiac repair[J]. Nat Commun,2021,12(1):1412.DOI:10.1038/s41467-021-21682-7.
• [55] Cheng G,Zhu D,Huang K,et al. Minimally invasive delivery of a hydrogel-based exosome patch to prevent heart failure[J].J Mol Cell Cardiol,2022,169:113-121. DOI:10.1016/j.yjmcc.2022.04.020.
• [56]朱恩灿，王伟伟，张闯年.海藻酸盐水凝胶治疗心肌梗死的研究进展[J].国际生物医学工程杂志，2024,47(3):268-274. DOI:10.3760/cma.j.cn121382-20240122-00310.
• [57] Bao S, Lu Y, Zhang J, et al. Rapid improvement of heart repair in rats after myocardial infarction by precise magnetic stimulation on the vagus nerve with an injectable magnetic hydrogel[J]. Nanoscale, 2023, 15(7):3532-3541.DOI:10.1039/d2nr05073k.
• [58] Sabbah HN, Wang M, Gupta RC, et al. Augmentation of left ventricular wall thickness with alginate hydrogel implants improves left ventricular function and prevents progressive remodeling in dogs with chronic heart failure[J]. JACC Heart failure, 2013, 1(3):252-258. DOI:10.1016/j.jchf.2013.02.006.